Prospective study of interaction between alcohol, NSAID use and polymorphisms in genes involved in the inflammatory response in relation to risk of colorectal cancer

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 624, Issue 1-2, 2007, Pages 88-100

  Vogel, Ulla ^a,b   Christensen, Jane ^c   Dybdahl, Marianne ^d   Friis, Søren ^c   Hansen, Rikke D ^a,c   Wallin, Håkan ^a   Nexø, Bjørn A ^e   Raaschou Nielsen, Ole ^c   Andersen, Paal S ^d   Overvad, Kim ^f   Tjønneland, Anne ^c  

^a NATIONAL RESEARCH CENTRE FOR THE WORKING ENVIRONMENT   (Denmark)

^b ROSKILDE UNIVERSITY   (Denmark)

^c INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

^d STATENS SERUM INSTITUT   (Denmark)

^e AARHUS UNIVERSITY   (Denmark)

^f AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Colorectal cancer; Gene environment interaction; Genetic epidemiology; IL1 ; IL10; IL6; IL8; Inflammation; NOD2; Polymorphism; PPAR gamma; Prospective study

Indexed keywords

ALANINE; CASPASE RECRUITMENT DOMAIN PROTEIN 15; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; PROLINE;

ADULT; ALCOHOL CONSUMPTION; ALLELE; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA POLYMORPHISM; DRUG ALCOHOL INTERACTION; ENTERITIS; ENVIRONMENTAL FACTOR; FEMALE; GENETIC EPIDEMIOLOGY; GENETIC VARIABILITY; HEREDITY; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; INFLAMMATION; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; RISK REDUCTION; STATISTICAL SIGNIFICANCE; WILD TYPE;

ADULT; ALCOHOL DRINKING; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BASE SEQUENCE; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; DNA PRIMERS; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 35348876076     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2007.04.006     Document Type: Article

References (55)

1. Schottelius A.J., and Dinter H. Cytokines, NF-kappaB, microenvironment, intestinal inflammation and cancer. Cancer Treat. Res. 130 (2006) 67-87
2. Vagefi P.A., and Longo W.E. Colorectal cancer in patients with inflammatory bowel disease. Clin. Colorectal Cancer 4 (2005) 313-319
3. Rhodes J.M., and Campbell B.J. Inflammation and colorectal cancer: IBD-associated and sporadic cancer compared. Trends Mol. Med. 8 (2002) 10-16
4. Ulrich C.M., Bigler J., and Potter J.D. Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat. Rev. Cancer 6 (2006) 130-140
5. Hawk E.T., and Levin B. Colorectal cancer prevention. J. Clin. Oncol. 23 (2005) 378-391
6. Norat T., Bingham S., Ferrari P., Slimani N., Jenab M., Mazuir M., Overvad K., Olsen A., Tjonneland A., Clavel F., Boutron-Ruault M.C., Kesse E., Boeing H., Bergmann M.M., Nieters A., Linseisen J., Trichopoulou A., Trichopoulos D., Tountas Y., Berrino F., Palli D., Panico S., Tumino R., Vineis P., Bueno-de-Mesquita H.B., Peeters P.H., Engeset D., Lund E., Skeie G., Ardanaz E., Gonzalez C., Navarro C., Quiros J.R., Sanchez M.J., Berglund G., Mattisson I., Hallmans G., Palmqvist R., Day N.E., Khaw K.T., Key T.J., San Joaquin M., Hemon B., Saracci R., Kaaks R., and Riboli E. Meat, fish, and colorectal cancer risk: the European prospective investigation into cancer and nutrition. J. Natl. Cancer Inst. 97 (2005) 906-916
7. Boffetta P., and Hashibe M. Alcohol and cancer. Lancet Oncol. 7 (2006) 149-156
8. Bingham S.A., Day N.E., Luben R., Ferrari P., Slimani N., Norat T., Clavel-Chapelon F., Kesse E., Nieters A., Boeing H., Tjonneland A., Overvad K., Martinez C., Dorronsoro M., Gonzalez C.A., Key T.J., Trichopoulou A., Naska A., Vineis P., Tumino R., Krogh V., Bueno-de-Mesquita H.B., Peeters P.H., Berglund G., Hallmans G., Lund E., Skeie G., Kaaks R., and Riboli E. Dietary fibre in food and protection against colorectal cancer in the European prospective investigation into cancer and nutrition (EPIC): an observational study. Lancet 361 (2003) 1496-1501
9. McCullough M.L., Robertson A.S., Chao A., Jacobs E.J., Stampfer M.J., Jacobs D.R., Diver W.R., Calle E.E., and Thun M.J. A prospective study of whole grains, fruits, vegetables and colon cancer risk. Cancer Causes Control 14 (2003) 959-970
10. Ji B.T., Weissfeld J.L., Chow W.H., Huang W.Y., Schoen R.E., and Hayes R.B. Tobacco smoking and colorectal hyperplastic and adenomatous polyps. Cancer Epidemiol. Biomarkers Prev. 15 (2006) 897-901
11. Giovannucci E. An updated review of the epidemiological evidence that cigarette smoking increases risk of colorectal cancer. Cancer Epidemiol. Biomarkers Prev. 10 (2001) 725-731
12. Crews F.T., Bechara R., Brown L.A., Guidot D.M., Mandrekar P., Oak S., Qin L., Szabo G., Wheeler M., and Zou J. Cytokines and alcohol. Alcohol Clin. Exp. Res. 30 (2006) 720-730
13. Saeed R.W., Varma S., Peng T., Tracey K.J., Sherry B., and Metz C.N. Ethanol blocks leukocyte recruitment and endothelial cell activation in vivo and in vitro. J. Immunol. 173 (2004) 6376-6383
14. d. van V., Postma D.S., Timens W., Hylkema M.N., Willemse B.W., Boezen H.M., Vonk J.M., de Reus D.M., Kauffman H.F., and ten Hacken N.H. Acute effects of cigarette smoking on inflammation in healthy intermittent smokers. Respir Res. 6 (2005) 22
15. Arber N., Eagle C.J., Spicak J., Racz I., Dite P., Hajer J., Zavoral M., Lechuga M.J., Gerletti P., Tang J., Rosenstein R.B., Macdonald K., Bhadra P., Fowler R., Wittes J., Zauber A.G., Solomon S.D., and Levin B. Celecoxib for the prevention of colorectal adenomatous polyps. N. Engl. J. Med. 355 (2006) 885-895
16. Bertagnolli M.M., Eagle C.J., Zauber A.G., Redston M., Solomon S.D., Kim K., Tang J., Rosenstein R.B., Wittes J., Corle D., Hess T.M., Woloj G.M., Boisserie F., Anderson W.F., Viner J.L., Bagheri D., Burn J., Chung D.C., Dewar T., Foley T.R., Hoffman N., Macrae F., Pruitt R.E., Saltzman J.R., Salzberg B., Sylwestrowicz T., Gordon G.B., and Hawk E.T. Celecoxib for the prevention of sporadic colorectal adenomas. N. Engl. J Med. 355 (2006) 873-884
17. Hansen R.D., Sorensen M., Tjonneland A., Overvad K., Wallin H., Raaschou-Nielsen O., and Vogel U. XPA A23G, XPC Lys939Gln, XPD Lys751Gln and XPD Asp312Asn polymorphisms, interactions with smoking, alcohol and dietary factors, and risk of colorectal cancer. Mutat. Res. 617 (2007) 68-80
18. Tjonneland A., Olsen A., Boll K., Stripp C., Christensen J., Engholm G., and Overvad K. Study design, exposure variables, and socioeconomic determinants of participation in Diet, Cancer and Health: a population-based prospective cohort study of 57,053 men and women in Denmark. Scand J. Pub. Health (2006)
19. Storm H.H., Michelsen E.V., Clemmensen I.H., and Pihl J. The Danish Cancer Registry-history, content, quality and use. Dan. Med. Bull. 44 (1997) 535-539
20. Miller S.A., Dykes D.D., and Polesky H.F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic. Acids Res. 16 (1988) 1215
21. Campa D., Zienolddiny S., Maggini V., Skaug V., Haugen A., and Canzian F. Association of a common polymorphism in the cyclooxygenase 2 gene with risk of non-small cell lung cancer. Carcinogenesis 25 (2004) 229-235
22. Macarthur M., Sharp L., Hold G.L., Little J., and El Omar E.M. The role of cytokine gene polymorphisms in colorectal cancer and their interaction with aspirin use in the northeast of Scotland. Cancer Epidemiol. Biomarkers Prev. 14 (2005) 1613-1618
23. Vogel U., Christensen J., Nexo B.A., Wallin H., Friis S., and Tjonneland A. Peroxisome proliferator-activated receptor{gamma}2 Pro12Ala, interaction with alcohol intake and NSAID use, in relation to risk of breast cancer in a prospective study of Danes. Carcinogenesis 28 (2007) 427-434
24. Vogel U., Christensen J., Wallin H., Friis S., Nexo B.A., and Tjonneland A. Polymorphisms in COX-2, NSAID use and risk of basal cell carcinoma in a prospective study of Danes. Mutat. Res. 617 (2007) 138-146
25. Vind I., Vieira A., Hougs L., Tavares L., Riis L., Andersen P.S., Locht H., Freitas J., Monteiro E., Christensen I.J., and Munkholm P. NOD2/CARD15 gene polymorphisms in Crohn's disease: a genotype-phenotype analysis in Danish and Portuguese patients and controls. Digestion 72 (2005) 156-163
26. Andersen P.S., Jespersgaard C., Vuust J., Christiansen M., and Larsen L.A. Capillary electrophoresis-based single strand DNA conformation analysis in high-throughput mutation screening. Hum. Mutat. 21 (2003) 455-465
27. Barlow W.E., Ichikawa L., Rosner D., and Izumi S. Analysis of case-cohort designs. J Clin Epidemiol. 52 (1999) 1165-1172
28. Barlow W.E. Robust variance estimation for the case-cohort design. Biometrics 50 (1994) 1064-1072
29. Greenland S. Avoiding power loss associated with categorization and ordinal scores in dose-response and trend analysis. Epidemiology 6 (1995) 450-454
30. Greenland S. Dose-response and trend analysis in epidemiology: alternatives to categorical analysis. Epidemiology 6 (1995) 356-365
31. Landi S., Moreno V., Gioia-Patricola L., Guino E., Navarro M., de Oca J., Capella G., and Canzian F. Association of common polymorphisms in inflammatory genes interleukin (IL)6, IL8, tumor necrosis factor alpha, NFKB1, and peroxisome proliferator-activated receptor gamma with colorectal cancer. Cancer Res. 63 (2003) 3560-3566
32. Goodman J.E., Mechanic L.E., Luke B.T., Ambs S., Chanock S., and Harris C.C. Exploring SNP-SNP interactions and colon cancer risk using polymorphism interaction analysis. Int. J. Cancer 118 (2006) 1790-1797
33. Murtaugh M.A., Ma K.N., Caan B.J., Sweeney C., Wolff R., Samowitz W.S., Potter J.D., and Slattery M.L. Interactions of peroxisome proliferator-activated receptor {gamma} and diet in etiology of colorectal cancer. Cancer Epidemiol. Biomarkers Prev. 14 (2005) 1224-1229
34. Slattery M.L., Curtin K., Wolff R., Ma K.N., Sweeney C., Murtaugh M., Potter J.D., Levin T.R., and Samowitz W. PPARgamma and colon and rectal cancer: associations with specific tumor mutations, aspirin, ibuprofen and insulin-related genes (United States). Cancer Causes Control 17 (2006) 239-249
35. Gong Z., Xie D., Deng Z., Bostick R.M., Muga S.J., Hurley T.G., and Hebert J.R. The PPAR{gamma} Pro12Ala polymorphism and risk for incident sporadic colorectal adenomas. Carcinogenesis 26 (2005) 579-585
36. Ota K., Ito K., Suzuki T., Saito S., Tamura M., Hayashi S., Okamura K., Sasano H., and Yaegashi N. Peroxisome proliferator-activated receptor gamma and growth inhibition by its ligands in uterine endometrial carcinoma. Clin. Cancer Res. 12 (2006) 4200-4208
37. Suzuki T., Hayashi S., Miki Y., Nakamura Y., Moriya T., Sugawara A., Ishida T., Ohuchi N., and Sasano H. Peroxisome proliferator-activated receptor gamma in human breast carcinoma: a modulator of estrogenic actions. Endocr. Relat. Cancer 13 (2006) 233-250
38. Bonofiglio D., Gabriele S., Aquila S., Catalano S., Gentile M., Middea E., Giordano F., and Ando S. Estrogen receptor alpha binds to peroxisome proliferator-activated receptor response element and negatively interferes with peroxisome proliferator-activated receptor gamma signaling in breast cancer cells. Clin. Cancer Res. 11 (2005) 6139-6147
39. Tjonneland A., Christensen J., Thomsen B.L., Olsen A., Overvad K., Ewertz M., and Mellemkjaer L. Hormone replacement therapy in relation to breast carcinoma incidence rate ratios: a prospective Danish cohort study. Cancer 100 (2004) 2328-2337
40. Fournier A., Berrino F., Riboli E., Avenel V., and Clavel-Chapelon F. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int. J. Cancer 114 (2005) 448-454
41. La Vecchia C., Gallus S., and Fernandez E. Hormone replacement therapy and colorectal cancer: an update. J. Br. Menopause. Soc. 11 (2005) 166-172
42. Gago-Dominguez M., Castelao J.E., Pike M.C., Sevanian A., and Haile R.W. Role of lipid peroxidation in the epidemiology and prevention of breast cancer. Cancer Epidemiol. Biomarkers Prev. 14 (2005) 2829-2839
43. Kurzawski G., Suchy J., Kladny J., Grabowska E., Mierzejewski M., Jakubowska A., Debniak T., Cybulski C., Kowalska E., Szych Z., Domagala W., Scott R.J., and Lubinski J. The NOD2 3020insC mutation and the risk of colorectal cancer. Cancer Res. 64 (2004) 1604-1606
44. Papaconstantinou I., Theodoropoulos G., Gazouli M., Panoussopoulos D., Mantzaris G.J., Felekouras E., and Bramis J. Association between mutations in the CARD15/NOD2 gene and colorectal cancer in a Greek population. Int. J. Cancer 114 (2005) 433-435
45. Medici V., Mascheretti S., Croucher P.J., Stoll M., Hampe J., Grebe J., Sturniolo G.C., Solberg C., Jahnsen J., Moum B., Schreiber S., and Vatn M.H. Extreme heterogeneity in CARD15 and DLG5 Crohn disease-associated polymorphisms between German and Norwegian populations. Eur. J. Hum. Genet. 14 (2006) 459-468
46. Gunter M.J., Canzian F., Landi S., Chanock S.J., Sinha R., and Rothman N. Inflammation-related gene polymorphisms and colorectal adenoma. Cancer Epidemiol. Biomarkers Prev. 15 (2006) 1126-1131
47. Fishman D., Faulds G., Jeffery R., Mohamed-Ali V., Yudkin J.S., Humphries S., and Woo P. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J. Clin. Invest. 102 (1998) 1369-1376
48. Hull J., Thomson A., and Kwiatkowski D. Association of respiratory syncytial virus bronchiolitis with the interleukin 8 gene region in UK families. Thorax 55 (2000) 1023-1027
49. Hwang I.R., Kodama T., Kikuchi S., Sakai K., Peterson L.E., Graham D.Y., and Yamaoka Y. Effect of interleukin 1 polymorphisms on gastric mucosal interleukin 1beta production in Helicobacter pylori infection. Gastroenterology 123 (2002) 1793-1803
50. Kilpinen S., Huhtala H., and Hurme M. The combination of the interleukin-1alpha (IL-1alpha-889) genotype and the interleukin-10 (IL-10 ATA) haplotype is associated with increased interleukin-10 (IL-10) plasma levels in healthy individuals. Eur. Cytokine Netw. 13 (2002) 66-71
51. Masugi J., Tamori Y., Mori H., Koike T., and Kasuga M. Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-gamma 2 on thiazolidinedione-induced adipogenesis. Biochem. Biophys. Res. Commun. 268 (2000) 178-182
52. Doney A., Fischer B., Frew D., Cumming A., Flavell D.M., World M., Montgomery H.E., Boyle D., Morris A., and Palmer C.N. Haplotype analysis of the PPARgamma Pro12Ala and C1431T variants reveals opposing associations with body weight. BMC Genet. 3 21 (2002) 21
53. Hugot J.P., Chamaillard M., Zouali H., Lesage S., Cezard J.P., Belaiche J., Almer S., Tysk C., O'Morain C.A., Gassull M., Binder V., Finkel Y., Cortot A., Modigliani R., Laurent-Puig P., Gower-Rousseau C., Macry J., Colombel J.F., Sahbatou M., and Thomas G. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411 (2001) 599-603
54. Peltekova V.D., Wintle R.F., Rubin L.A., Amos C.I., Huang Q., Gu X., Newman B., Van Oene M., Cescon D., Greenberg G., Griffiths A.M., George-Hyslop P.H., and Siminovitch K.A. Functional variants of OCTN cation transporter genes are associated with Crohn's disease. Nat. Genet. 36 (2004) 471-475
55. Stoll M., Corneliussen B., Costello C.M., Waetzig G.H., Mellgard B., Koch W.A., Rosenstiel P., Albrecht M., Croucher P.J., Seegert D., Nikolaus S., Hampe J., Lengauer T., Pierrou S., Foelsch U.R., Mathew C.G., Lagerstrom-Fermer M., and Schreiber S. Genetic variation in DLG5 is associated with inflammatory bowel disease. Nat. Genet. 36 (2004) 476-480